Results 111 to 120 of about 67,063 (322)

Prosthodontic care and management of patients with MRONJ from different microbiological backgrounds

Fogorvosi Szemle
Medication-related osteonecrosis of the Jaw (MRONJ) is a severe condition of multifactorial origin, with its exact etiological factors still not fully understood.
Flóra Alíz Lakatos, László Kádár, Péter Schmidt, János König, Andrea Bródy, Károly Frigyes Mensch   +5 more
doaj   +1 more source

Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)

Dentistry Journal, 2016
Since the first description of bisphosphonate-related osteonecrosis of the jaw (BRONJ), numerous research groups have focused on possible pathological mechanisms including the suppression of the bone turnover of the jaw, antiangiogenic effects and soft ...
Thomas Ziebart, Frank Halling, Paul Heymann, Andreas Neff, Sebastian Blatt, Junho Jung, Andreas Pabst, Leonardo Righesso, Christian Walter   +8 more
doaj   +1 more source

New Advances of Degradable Magnesium‐Based Metal Biomaterials in the Field of Orthopedics

Rare Metals, EarlyView.
ABSTRACT Based on their outstanding biomechanical properties and superior osteogenic activity, magnesium (Mg) and its alloys have been extensively investigated for their biocompatibility and therapeutic efficacy in treating fractures and bone defects.
Jia‐Nan Yu, Shao‐Sheng Jia, Rong‐Bang Sun, Tong Zhang, Ling‐Chuang Bai, Di Mei, Shi‐Jie Zhu, Lan Chen, Shao‐Kang Guan   +8 more
wiley   +1 more source

NIR‐Responsive Nano‐Integrated Magnesium Phosphate Cement Promotes Bone Regeneration via Osteoblast‐Exosome‐Osteoclast Crosstalk

Rare Metals, EarlyView.
ABSTRACT The limited osteogenic capacity of magnesium phosphate cement (MPC) has constrained its biomedical applications, underscoring the necessity to develop MPC with enhanced physical properties and bone‐forming capabilities. In this study, a multifunctional MPC system was developed by incorporating zoledronic acid‐loaded near‐infrared (NIR ...
Bin Wang, Shun‐Jie Wu, Xin‐Lin Lu, Yong Ge, Yue Zhang, Zhi‐Xiang Ma, Bin Xu, Paul‐K. Chu, Yan‐Bin Zhao   +8 more
wiley   +1 more source

How should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? [PDF]

, 2005
If bone density is evaluated after initiating bisphosphonate drug therapy, it should be tested no earlier than 2 years (strength of recommendation [SOR]: B, based on case series of dual energy x-ray absorptiometry [DEXA] scanning precision and ...
Easterling, Lisa, Koval, Peter G., Mackler, Leslie, Pettus, Dawn   +3 more
core  

Treatment with intravenous bisphosphonates in children and adolescents with Osteogenesis Imperfecta: are we towards a consensus of a protocol? [PDF]

, 2018
Konstantinos Stathopoulos
openalex   +1 more source

Defect‐Passivating and Dense Indolocarbazole‐Based Self‐Assembled Monolayers for Efficient Inverted Perovskite Solar Cells With over 26.1% Efficiency

Small, EarlyView.
This study proposes a strategy to modulate nitrogen positions (meta‐/para‐) in indolocarbazole units and the number of anchoring groups (mono‐/bis‐phosphonate), achieving a remarkable PCE of 26.12%, among the highest reported for PSCs using indolocarbazole‐based SAMs as HTLs.
Xu Fu, Yuxuan Yang, Dingqian He, Peng Zhao, Huixin Gao, Zhen Zhu, Yi Zhang, Bao Zhang, Mohammad Khaja Nazeeruddin   +8 more
wiley   +1 more source

Submental Perforator Flap for Soft-Tissue Reconstruction in Bisphosphonate-Related Osteonecrosis of the Jaws [PDF]

, 2016
Jose-Antonio García-de Marcos, J Rey-Biel   +1 more
openalex   +1 more source

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study [PDF]

, 2021
Chiara Marocco, Giovanna Zimatore, Edoardo Mocini, Rachele Fornari, Giovanni Iolascon, Maria Chiara Gallotta, Viviana Maria Bimonte, Carlo Baldari, Andrea Lenzi, Silvia Migliaccio   +9 more
openalex   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source